Examining the Causes and Consequences of Increasing Insulin Costs With Prospective Interventions

Am J Ther. 2020 Jan/Feb;27(1):e115-e120. doi: 10.1097/MJT.0000000000001111.
No abstract available

MeSH terms

  • Biosimilar Pharmaceuticals / economics*
  • Cost Savings
  • Drug Industry / economics
  • Drug Industry / organization & administration*
  • Europe
  • Humans
  • Hypoglycemic Agents / economics*
  • Insulin / economics*
  • Prospective Studies
  • United States

Substances

  • Biosimilar Pharmaceuticals
  • Hypoglycemic Agents
  • Insulin